详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Orthopaedic Research Institute, Department of Orthopaedics, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, People’s Republic of China [2]Sarcoma Biology Laboratory, Department of Orthopaedics, Sylvester Comprehensive Cancer Center, the University of Miami Miller School of Medicine, Miami, FL, 33136, USA [3]Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90095, USA

出处：

DOI：

ISSN：

关键词： Osteosarcoma Immune checkpoint inhibitor Immunotherapy PD-L1 CTLA-4

摘要：

Osteosarcoma is the most common primary malignant bone tumor and is associated with a high risk of recurrence and distant metastasis. Effective treatment for osteosarcoma, especially advanced osteosarcoma, has stagnated over the past four decades. The advent of immune checkpoint inhibitor (ICI) has transformed the treatment paradigm for multiple malignant tumor types and indicated a potential therapeutic strategy for osteosarcoma. In this review, we discuss recent advances in immune checkpoints, including programmed cell death protein-1 (PD-1), programmed cell death protein ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and their related ICIs for osteosarcoma treatment. We present the main existing mechanisms of resistance to ICIs therapy in osteosarcoma. Moreover, we summarize the current strategies for improving the efficacy of ICIs in osteosarcoma and address the potential predictive biomarkers of ICIs treatment in osteosarcoma.Copyright © 2022. Published by Elsevier B.V.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学

第一作者：

第一作者机构： [1]Orthopaedic Research Institute, Department of Orthopaedics, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, People’s Republic of China

共同第一作者：

通讯作者：

通讯机构： [1]Orthopaedic Research Institute, Department of Orthopaedics, West China Hospital, Sichuan University, Guoxue Xiang No. 37, Chengdu, 610041, Sichuan, People’s Republic of China [2]Sarcoma Biology Laboratory, Department of Orthopaedics, Sylvester Comprehensive Cancer Center, the University of Miami Miller School of Medicine, Miami, FL, 33136, USA [3]Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90095, USA [*1]Sarcoma Biology Laboratory, Department of Orthopaedics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Papanicolaou Cancer Research Building, 1550 NW. 10th Avenue, Miami, FL, 33136, USA. [*2]Orthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A PD-1 /PD-L1 proximity assay as a theranostic marker for PD-1 blockade in patients with metastatic melanoma. [2]ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. [3]Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. [4]Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation [5]PD-1/PD-L1在肝细胞癌治疗中的研究进展 [6]Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period [7]Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy [8]Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy [9]Immune landscape and immunotherapy for penile cancer [10]Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials